danazol has been researched along with icatibant in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Daudén, E; García-Diez, A; Pedraz, J | 1 |
| Bernstein, IL | 1 |
| Firszt, R; Frank, MM | 1 |
| Bork, K | 1 |
| Bygum, A | 1 |
| Farmaki, E; Germenis, AE; Koutsostathis, N; Psarros, F; Speletas, MG | 1 |
| Banerji, A; Bernstein, JA; Busse, P; Christiansen, S; Craig, T; Davis-Lorton, M; Frank, MM; Li, HH; Lumry, WR; Riedl, M; Zuraw, B | 1 |
| Andresen, I; Botha, J; Graif, Y; Kivity, S; Reshef, A; Toubi, E | 1 |
4 review(s) available for danazol and icatibant
| Article | Year |
|---|---|
[Practical management of C1 inhibitor deficiency].
Topics: Adolescent; Adult; Aminocaproic Acid; Angioedema; Bradykinin; Child; Child, Preschool; Complement C1 Inhibitor Protein; Complement C4; Danazol; Disease Management; Estrogens; Female; Humans; Intraoperative Complications; Male; Middle Aged; Serine Proteinase Inhibitors; Tranexamic Acid | 2007 |
Hereditary angioedema: a current state-of-the-art review, II: historical perspective of non-histamine-induced angioedema.
Topics: Adrenergic beta-Antagonists; Angioedemas, Hereditary; Animals; Bradykinin; Clinical Trials as Topic; Complement C1 Inactivator Proteins; Complement C2; Danazol; Disease Models, Animal; Factor XIIa; Genetic Linkage; Humans; Kallikreins; Mice; Peptides; Research | 2008 |
An overview of novel therapies for acute hereditary angioedema.
Topics: Acute Disease; Adrenergic beta-Antagonists; Androgens; Antifibrinolytic Agents; Bradykinin; Bradykinin Receptor Antagonists; Complement C1 Inhibitor Protein; Danazol; Hereditary Angioedema Type III; Hereditary Angioedema Types I and II; Hormone Antagonists; Humans; Kallikreins; Peptides; Tranexamic Acid | 2010 |
Current management options for hereditary angioedema.
Topics: Angioedemas, Hereditary; Bradykinin; Complement C1 Inhibitor Protein; Danazol; Disease Management; Humans; Oxandrolone; Peptides; Plasma; Recombinant Proteins; Stanozolol | 2012 |
4 other study(ies) available for danazol and icatibant
| Article | Year |
|---|---|
Hereditary angioedema - consequences of a new treatment paradigm in Denmark.
Topics: Activities of Daily Living; Administration, Cutaneous; Adult; Aged; Angioedemas, Hereditary; Bradykinin; Complement C1 Inhibitor Protein; Cost of Illness; Danazol; Denmark; Dermatologic Agents; Disease Progression; Drug Administration Schedule; Female; Home Care Services; Hospitalization; Humans; Male; Middle Aged; Motor Activity; Prospective Studies; Quality of Life; Registries; Time Factors; Tranexamic Acid; Treatment Outcome | 2014 |
Hereditary angioedema in Greece: the first results of the greek hereditary angioedema registry.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angioedemas, Hereditary; Anti-Inflammatory Agents, Non-Steroidal; Bradykinin; Child; Child, Preschool; Danazol; Estrogen Antagonists; Female; Follow-Up Studies; Greece; Humans; Male; Middle Aged; Quality of Life; Registries; Surveys and Questionnaires; Young Adult | 2014 |
Management of Children With Hereditary Angioedema Due to C1 Inhibitor Deficiency.
Topics: Adolescent; Angioedemas, Hereditary; Anti-Inflammatory Agents, Non-Steroidal; Antifibrinolytic Agents; Bradykinin; Child; Complement C1 Inactivator Proteins; Complement C1 Inhibitor Protein; Danazol; Genetic Testing; Humans; Patient Care Team; Patient Education as Topic; Peptides; Recombinant Proteins; Tranexamic Acid | 2016 |
Icatibant Outcome Survey in Patients with Hereditary Angioedema: Experience in Israel Compared with Other Countries.
Topics: Adult; Aged; Aged, 80 and over; Angioedemas, Hereditary; Anti-Inflammatory Agents, Non-Steroidal; Bradykinin; Danazol; Delayed Diagnosis; Female; Follow-Up Studies; Humans; Israel; Male; Middle Aged; Prospective Studies; Registries; Self Administration; Severity of Illness Index; Surveys and Questionnaires; Time Factors; Treatment Outcome; Young Adult | 2018 |